No Data
No Data
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5
BioXcel Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | BioXcel Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7
BioXcel Announces Defense Grant to UNC to Fund Study for Treating Acute Stress Disorder
Express News | BioXcel Therapeutics Inc - Phase 2a Trial Enrollment Expected in H1 2025
Express News | BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder